Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial.
- Hansen, Mathias Lühr
- Pellicer, Adelina
- Gluud, Christian
- Dempsey, Eugene
- Mintzer, Jonathan
- Hyttel-Sørensen, Simon
- Heuchan, Anne Marie
- Hagmann, Cornelia
- Ergenekon, Ebru
- Dimitriou, Gabriel
- Pichler, Gerhard
- Naulaers, Gunnar
- Cheng, Guoqiang
- Guimarães, Hercilia
- Tkaczyk, Jakub
- Kreutzer, Karen B
- Fumagalli, Monica
- Claris, Olivier
- Lemmers, Petra
- Fredly, Siv
- Szczapa, Tomasz
- Austin, Topun
- Jakobsen, Janus Christian
- Greisen, Gorm
Publication date
December 2019
DOI Publisher
Springer Science and Business Media LLC Journal
TrialsAbstract
Cerebral oxygenation monitoring may reduce the risk of death and neurologic complications in extremely preterm infants, but no such effects have yet been demonstrated in preterm infants in sufficiently powered randomised clinical trials. The objective of the SafeBoosC III trial is to investigate the benefits and harms of treatment based on near-infrared spectroscopy (NIRS) monitoring compared with treatment as usual for extremely preterm infants
Add to ORKG